At the 2016 AHIP Institute and Expo, ORC International and McKesson Health Solutions shared the results of their recent study on the latest trends in value-based reimbursement. This webinar will share previously unreleased information regarding the technologies providers and payers are seeking to support their journey to value based reimbursement. McKesson will also introduce how connecting payer systems can help accelerate the value realized from value-based models.
This webinar will help payers and providers better understand the evolution of value-based reimbursement and identify approaches they can consider to support their organizations shift to value-based payments.
By participating in this webinar:
Who should attend: Health Plans, Physicians and Facilities
Andrei Gonzales, MD, Director VBR Initiatives, McKesson Health Solutions
Dr. Andrei Gonzales is Director, Value Based Reimbursement Initiatives at McKesson Health Solutions, leading strategic customer engagements to develop and implement McKesson’s risk based payment capabilities. Prior to this role, he managed customer engagements and provided expert guidance to help customers develop and establish pilot programs using the McKesson Episode Management solution.
Dr. Gonzales has been with McKesson for nine years, first managing physician-oriented acute care solutions at McKesson Provider Technologies. Prior to joining McKesson, he led product management for Medtronic Navigation’s cranial image guided surgery team and physician solutions at Thomson Micromedex. He received his MD from the University of Washington, School of Medicine.
Dana Benini, Vice President, ORC International
Dana has been with ORC for 14 years helping clients adapt to a changing healthcare landscape. Dana specializes in the integration of secondary research, primary CI and qualitative research methodologies to inform product and program development. Dana came to ORC International from GlaxoSmithKline’s Competitive Intelligence department, where she served on the Rheumatology Disease Area Strategy Team, informing on the competitor drug research & development landscape. She also served on the rheumatoid arthritis in-licensing team, for which she helped identify in-licensing opportunities and develop a target product profile for drugs in this indication.
Prior to GSK, Dana worked at Hoffman-La Roche as an Information Scientist, supporting oncology research and development. Dana previously worked in a laboratory of the Tufts-New England Medical Center Department of Pathology studying the CD43 function on murine lymphocyte adhesion. Dana has a Bachelor of Science in Biochemistry and Molecular Biology from Pennsylvania State University.